PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study found that BRCA2 mutations are a predictor of venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients on poly-(ADP-ribose) polymerase inhibitors (iPARP). Bevacizumab may reduce VTE/AT risk.
Area Of Science
- Oncology
- Thrombosis Research
- Pharmacovigilance
Background
- Ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP) face risks of thromboembolic events.
- Identifying predictive factors for these events is crucial for patient management.
Purpose Of The Study
- To determine the incidence of venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients receiving iPARP therapy.
- To identify predictive factors for VTE/AT and assess the impact of these events on overall survival.
Main Methods
- A multicenter retrospective study of 329 ovarian cancer patients treated with iPARP.
- Analysis included logistic regression for predictive factors and Kaplan-Meier analysis for survival outcomes.
Main Results
- The incidence of VTE/AT was 4.9%.
- BRCA2 mutations were significantly associated with increased VTE/AT risk (56.3% vs. 19.2%; p < 0.001).
- Concomitant bevacizumab treatment showed a protective association against thrombosis (OR: 0.262; p = 0.010).
Conclusions
- BRCA2 mutations are a significant predictor for VTE/AT in ovarian cancer patients on iPARP.
- Bevacizumab may reduce thrombotic event risk, though bias is possible.
- Findings inform thromboprophylaxis strategies in clinical trials.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...